Omicia and the University of Utah said this week that they have signed a two-year licensing agreement that allows researchers involved in the Utah Genome Project use Opal, Omicia's platform for analyzing genomics in research and clinical applications, to analyze disease causing variants.
The Utah Genome Project is a large-scale, genome sequencing and analysis initiative that aims to discover new disease-causing genes and develop more personalized testing and treatment procedures. Under the terms of the agreement, researchers and clinicians involved in the project will be able to use Opal on a cost-per-genome basis to identify variants that are associated with autoimmune and metabolic disorders and other ailments.
The financial details of the agreement were not disclosed.